Bone metastasis: The importance of the neighbourhood

Nature Reviews Cancer

Volumn 16, Issue 6, 2016, Pages 373-386

  Croucher, Peter I ^a,b,c   McDonald, Michelle M ^a,b   Martin, T John ^d,e  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BONE CELL; BONE METASTASIS; BONE REMODELING; BONE TURNOVER; CANCER CELL; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CELL SURVIVAL; DORMANCY; HUMAN; METASTASIS; OSTEOBLAST; OSTEOCLAST; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SKELETON; STEM CELL NICHE; TUMOR INVASION; TUMOR MICROENVIRONMENT; BONE NEOPLASMS; SECONDARY;

BONE NEOPLASMS; BONE REMODELING; HUMANS; TUMOR MICROENVIRONMENT;

EID: 84970966426     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.44     Document Type: Review

References (221)

1. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3, 453-458 (2003
2. Mundy, G. R., & Martin, T. J. in Physiology and Pharmacology of Bone (ed. Mundy, G. R., & Martin, T. J.) 641-671 (Springer-Verlag, 1993
3. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889
4. Fidler, I. J., & Kripke, M. L. The challenge of targeting metastasis. Cancer Metastasis Rev. 34, 635-641 (2015
5. Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411-425 (2011
6. Sterling, J. A., Edwards, J. R., Martin, T. J., & Mundy, G. R. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone 48, 6-15 (2011
7. Chambers, A. F., Groom, A. C., & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002
8. Cameron, M. D., et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 60, 2541-2546 (2000
9. Luzzi, K. J., et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153, 865-873 (1998
10. Ottewell, P. D., et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20, 2922-2932 (2014). One of the first studies to show that the bone microenvironment can control metastasis development.
11. Ottewell, P. D., et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer 21, 769-781 (2014
12. Wang, N., et al. Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis - evidence from in vivo models. J. Bone Miner. Res. 29, 2688-2696 (2014
13. Lawson, M. A., et al. Osteoclasts control reactivation of dormant myeloma cells by remodeling the endosteal niche. Nat. Commun. 6, 8983 (2015)
14. Fortunato, L., et al. Positive bone marrow biopsy is associated with a decreased disease-free survival in patients with operable breast cancer. Ann. Surg. Oncol. 16, 3010-3019 (2009
15. Tjensvoll, K., et al. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer 12, 190 (2012
16. Domschke, C., et al. Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow up study. Ann. Surg. Oncol. 20, 1865-1871 (2013
17. Boyle, W. J., Simonet, W. S., & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003
18. Suda, T., et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345-357 (1999
19. Baron, R. Molecular mechanisms of bone resorption by the osteoclast. Anat. Rec. 224, 317-324 (1989
20. Andersen, T. L., et al. Understanding coupling between bone resorption and formation: are reversal cells the missing link?. Am. J. Pathol. 183, 235-246 (2013
21. Delaisse, J. M. The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation. Bonekey Rep. 3, 561 (2014
22. Kassem, M., & Bianco, P. Skeletal stem cells in space and time. Cell 160, 17-19 (2015
23. Kim, S. W., et al. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J. Bone Miner. Res. 27, 2075-2084 (2012
24. Mizoguchi, T., et al. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. Dev. Cell 29, 340-349 (2014
25. Martin, T. J., & Sims, N. A. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. BoneKey Rep. 3, 215 (2014
26. Sims, N. A., & Martin, T. J. Coupling signals between the osteoclast and osteoblast: how are messages transmitted between these temporary visitors to the bone surface?. Front. Endocrinol. (Lausanne) 6, 41 (2015
27. Martin, T. J., Ng, K. W., & Sims, N. A. in Translational Endocrinology of Bone (ed. Karsenty, G.) 5-26 (Elsevier Inc, 2013
28. Kalajzic, Z., et al. Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor population. Bone 43, 501-510 (2008
29. Acar, M., et al. Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature 526, 126-130 (2015
30. Hattner, R., Epker, B. N., & Frost, H. M. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206, 489-490 (1965
31. Rodan, G. A., & Martin, T. J. Role of osteoblasts in hormonal control of bone resorption-A hypothesis. Calcif. Tissue Int. 33, 349-351 (1981
32. Parfitt, A. M. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab. Bone Dis. Relat. Res. 4, 1-6 (1982
33. Martin, T. J., & Sims, N. A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81 (2005
34. Xian, L., et al. Matrix IGF 1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat. Med. 18, 1095-1101 (2012
35. Weivoda, M. M., et al. Osteoclast TGF-β receptor signaling induces Wnt1 secretion and couples bone resorption to bone formation. J. Bone Miner. Res. 31, 76-85 (2015
36. Mundy, G. R. Mechanisms of bone metastasis. Cancer 80, 1546-1556 (1997
37. Kozlow, W., & Guise, T. A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J. Mammary Gland Biol. Neoplasia 10, 169-180 (2005
38. Andersen, T. L., et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am. J. Pathol. 174, 239-247 (2009
39. Kristensen, H. B., Andersen, T. L., Marcussen, N., Rolighed, L., & Delaisse, J. M. Increased presence of capillaries next to remodeling sites in adult human cancellous bone. J. Bone Miner. Res. 28, 574-585 (2013
40. Hauge, E. M., Qvesel, D., Eriksen, E. F., Mosekilde, L., & Melsen, F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J. Bone Miner. Res. 16, 1575-1582 (2001
41. Kristensen, H. B., Andersen, T. L., Marcussen, N., Rolighed, L., & Delaisse, J. M. Osteoblast recruitment routes in human cancellous bone remodeling. Am. J. Pathol. 184, 778-789 (2014
42. Eriksen, E. F., Eghbali-Fatourechi, G. Z., & Khosla, S. Remodeling and vascular spaces in bone. J. Bone Miner. Res. 22, 1-6 (2007
43. Andersen, T. L., Soe, K., Sondergaard, T. E., Plesner, T., & Delaisse, J. M. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br. J. Haematol. 148, 551-561 (2010
44. Yamaguchi, K., Croucher, P. I., & Compston, J. E. Comparison between the lengths of individual osteoid seams and resorption cavities in human iliac crest cancellous bone. Bone Miner. 23, 27-33 (1993
45. Chang, M. K., et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo. J. Immunol. 181, 1232-1244 (2008
46. Schofield, R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4, 7-25 (1978
47. Nilsson, S. K., Johnston, H. M., & Coverdale, J. A. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood 97, 2293-2299 (2001
48. Calvi, L. M., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003
49. Zhang, J., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841 (2003
50. Bianco, P. Minireview: The stem cell next door: skeletal and hematopoietic stem cell "niches" in bone. Endocrinology 152, 2957-2962 (2011
51. Askmyr, M., Sims, N. A., Martin, T. J., & Purton, L. E. What is the true nature of the osteoblastic hematopoietic stem cell niche?. Trends Endocrinol. Metab. 20, 303-309 (2009
52. Bianco, P. Bone and the hematopoietic niche: a tale of two stem cells. Blood 117, 5281-5288 (2011
53. Doherty, M. J., et al. Vascular pericytes express osteogenic potential in vitro and in vivo. J. Bone Miner. Res. 13, 828-838 (1998
54. Sacchetti, B., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324-336 (2007
55. Xie, Y., et al. Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457, 97-101 (2009
56. Lo Celso, C., et al. Live-Animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 457, 92-96 (2009
57. Chan, C. K., et al. Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature 457, 490-494 (2009
58. Kode, A., et al. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 506, 240-244 (2014
59. Ding, L., & Morrison, S. J. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature 495, 231-235 (2013
60. Greenbaum, A., et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature 495, 227-230 (2013
61. Van ?t Veer, L. J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002
62. Van De Vijver, M. J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002
63. Weigelt, B., et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA 100, 15901-15905 (2003
64. Kang, Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003
65. Zhang, X. H., et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16, 67-78 (2009
66. Padua, D., et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77 (2008
67. Zhang, X. H., et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154, 1060-1073 (2013
68. Jung, Y., et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat. Commun. 4, 1795 (2013
69. Bidwell, B. N., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224-1231 (2012
70. Vecchi, M., et al. Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27, 2148-2158 (2008
71. Ki, D. H., et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int. J. Cancer 121, 2005-2012 (2007
72. Stoecklein, N. H., & Klein, C. A. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int. J. Cancer 126, 589-598 (2010
73. Klein, C. A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302-312 (2009
74. Hong, M. K., et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015
75. Gundem, G., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015
76. Butcher, D. T., Alliston, T., & Weaver, V. M. A tense situation: forcing tumour progression. Nat. Rev. Cancer 9, 108-122 (2009
77. Paszek, M. J., & Weaver, V. M. The tension mounts: mechanics meets morphogenesis and malignancy. J. Mammary Gland Biol. Neoplasia 9, 325-342 (2004
78. Guelcher, S. A., Dumas, J. Srinivasan, A., Didier, J. E., & Hollinger, J. O. Synthesis, mechanical properties, biocompatibility, and biodegradation of polyurethane networks from lysine polyisocyanates. Biomaterials 29, 1762-1775 (2008
79. Johnson, R. W., et al. TGF-β promotion of Gli2 induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 71, 822-831 (2011
80. Ruppender, N. S., et al. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS ONE 5, e15451 (2010
81. Muller, A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001
82. Taichman, R. S., et al. Use of the stromal cell-derived factor 1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62, 1832-1837 (2002
83. Corcoran, K. E., et al. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS ONE 3, e2563 (2008
84. Correa, D., Somoza, R. A., Lin, P., Schiemann, W. P., & Caplan, A. I. Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche. Int. J. Cancer 138, 417-427 (2015
85. Loibl, M., et al. Direct cell-cell contact between mesenchymal stem cells and endothelial progenitor cells induces a pericyte-like phenotype in vitro. Biomed. Res. Int. 2014, 395781 (2014
86. Parmo-Cabanas, M., et al. Integrin a4β1 involvement in stromal cell-derived factor 1a promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp. Cell Res. 294, 571-580 (2004
87. Sanz-Rodriguez, F., Hidalgo, A., & Teixido, J. Chemokine stromal cell-derived factor 1a modulates VLA 4 integrin-mediated multiple myeloma cell adhesion to CS 1/fibronectin and VCAM 1. Blood 97, 346-351 (2001
88. Abe, M., Hiura, K., Ozaki, S., Kido, S., & Matsumoto, T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA 4- VCAM 1 adhesion and macrophage inflammatory protein 1a and MIP 1β production. J. Bone Miner. Metab. 27, 16-23 (2009
89. Choi, S. J., et al. Macrophage inflammatory protein 1 a is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96, 671-675 (2000
90. Oyajobi, B. O., et al. Dual effects of macrophage inflammatory protein 1a on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102, 311-319 (2003
91. Azab, A. K., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341-4351 (2009
92. Domanska, U. M., et al. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14, 709-718 (2012
93. Xiang, J., et al. CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. Mol. Cancer Ther. 14, 2473-2485 (2015
94. Liapis, H., Flath, A., & Kitazawa, S. Integrin aVβ3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol. 5, 127-135 (1996
95. Carlson, C. S., et al. Immunolocalization of noncollagenous bone matrix proteins in lumbar vertebrae from intact and surgically menopausal cynomolgus monkeys. J. Bone Miner. Res. 8, 71-81 (1993
96. Grzesik, W. J., & Robey, P. G. Bone matrix RGD glycoproteins: immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J. Bone Miner. Res. 9, 487-496 (1994
97. Wang, H., et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27, 193-210 (2015
98. Beausoleil, M. S., Schulze, E. B., Goodale, D., Postenka, C. O., & Allan, A. L. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer 11, 25 (2011
99. Klevesath, M. B., et al. Patterns of metastatic spread in early breast cancer. Breast 22, 449-454 (2013
100. Sung, V., Stubbs, J. T. 3rd, Fisher, L., Aaron, A. D., & Thompson, E. W. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the avβ3 and avβ5 integrins. J. Cell. Physiol. 176, 482-494 (1998
101. Adwan, H., et al. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA MB 231 cells. Int. J. Oncol. 24, 1235-1244 (2004
102. Wang, J., et al. BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA MB 231BO human breast cancer cells. PLoS ONE 8, e62936 (2013
103. Uchiyama, H., Barut, B. A., Chauhan, D., Cannistra, S. A., & Anderson, K. C. Characterization of adhesion molecules on human myeloma cell lines. Blood 80, 2306-2314 (1992
104. Mori, Y., et al. Anti a4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149-2154 (2004
105. Jones, D. H., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006
106. Thomas, R. J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140, 4451-4458 (1999
107. Nannuru, K. C., et al. Enhanced expression and shedding of receptor activator of NF ?.B ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis. Clin. Exp. Metastasis 26, 797-808 (2009
108. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002
109. Pearse, R. N., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl Acad. Sci. USA 98, 11581-11586 (2001
110. Zhang, J., et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107, 1235-1244 (2001
111. Croucher, P. I., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98, 3534-3540 (2001
112. Canon, J. R., et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25, 119-129 (2008
113. Armstrong, A. P., et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68, 92-104 (2008
114. Campbell, J. P., et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 10, e1001363 (2012
115. Shiozawa, Y., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312 (2011
116. Vanderkerken, K., et al. Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br. J. Cancer 82, 953-959 (2000
117. Chen, Z., Orlowski, R. Z., Wang, M., Kwak, L., & McCarty, N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123, 2204-2208 (2014
118. Karadag, A., Oyajobi, B. O., Apperley, J. F., Russell, R. G. G., & Croucher, P. I. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br. J. Haematol. 108, 383-390 (2000
119. Ro, T. B., et al. Bone morphogenetic protein 5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23, 3024-3032 (2004
120. Hjertner, O., et al. Bone morphogenetic protein 4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97, 516-522 (2001
121. Kawamura, C., et al. Bone morphogenetic protein 2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96, 2005-2011 (2000
122. Holien, T., & Sundan, A. The role of bone morphogenetic proteins in myeloma cell survival. Cytokine Growth Factor Rev. 25, 343-350 (2014
123. Dosen, G., et al. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol. 7, 13 (2006
124. Li, X., Pennisi, A., & Yaccoby, S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 112, 159-168 (2008
125. D'Souza, S., et al. Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. Blood 119, 1888-1896 (2012
126. Holen, I., Croucher, P. I., Hamdy, F. C., & Eaton, C. L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619-1623 (2002
127. Shipman, C. M., & Croucher, P. I. Osteoprotegerin is a soluble decoy receptor for tumour necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912-916 (2003
128. Nyambo, R., et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J. Bone Miner. Res. 19, 1712-1721 (2004
129. Neville-Webbe, H. L., et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat. 86, 269-279 (2004
130. Vitovski, S., Phillips, J. S., Sayers, J., & Croucher, P. I. Investigating the interaction between osteoprotegerin and receptor activator of NF ?.B or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282, 31601-31609 (2007
131. Schlimok, G., et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti 17 1A monoclonal antibodies. Proc. Natl Acad. Sci. USA 84, 8672-8676 (1987
132. Cote, R. J., et al. Monoclonal antibodies detect occult breast carcinoma metastases in the bone marrow of patients with early stage disease. Am. J. Surg. Pathol. 12, 333-340 (1988
133. Pantel, K., et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347, 649-653 (1996
134. Engel, J., et al. The process of metastasisation for breast cancer. Eur. J. Cancer 39, 1794-1806 (2003
135. Husemann, Y., et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008
136. Shiozawa, Y., et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12, 116-127 (2010
137. Jung, Y., et al. Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia 14, 429-439 (2012
138. Taichman, R. S., et al. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS ONE 8, e61873 (2013
139. Mishra, A., et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol. Cancer Res. 10, 703-712 (2012
140. Kusumbe, A. P., Ramasamy, S. K., & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323-328 (2014
141. Spencer, J. A., et al. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 508, 269-273 (2014
142. Ghajar, C. M. Metastasis prevention by targeting the dormant niche. Nat. Rev. Cancer 15, 238-247 (2015
143. Ghajar, C. M., et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 15, 807-817 (2013
144. Horiuchi, K., et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor β. J. Bone Miner. Res. 14, 1239-1249 (1999
145. Merle, B., Bouet, G., Rousseau, J. C., Bertholon, C., & Garnero, P. Periostin and transforming growth factor β-induced protein (TGFβIp) are both expressed by osteoblasts and osteoclasts. Cell Biol. Int. 38, 398-404 (2014
146. Malanchi, I., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2012
147. Lee, Y. J., et al. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol. Ther. 21, 1004-1013 (2013
148. Yin, J. J., et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206 (1999
149. Kakonen, S. M., et al. Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-Activated protein kinase signaling pathways. J. Biol. Chem. 277, 24571-24578 (2002
150. Fournier, P. G., et al. The TGF-β signaling regulator PMEPA1 suppresses prostate cancer metastases to bone. Cancer Cell 27, 809-821 (2015
151. Pettit, A. R., Chang, M. K., Hume, D. A., & Raggatt, L. J. Osteal macrophages: a new twist on coupling during bone dynamics. Bone 43, 976-982 (2008
152. Parfitt, A. M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J. Cell Biochem. 55, 273-286 (1994
153. Lu, X., et al. VCAM 1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging a4β1 positive osteoclast progenitors. Cancer Cell 20, 701-714 (2011
154. Chen, Q., Zhang, X. H., & Massague, J. Macrophage binding to receptor VCAM 1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20, 538-549 (2011
155. Hynes, R. O. Metastatic cells will take any help they can get. Cancer Cell 20, 689-690 (2011
156. Giancotti, F. G. Mechanisms governing metastatic dormancy and reactivation. Cell 155, 750-764 (2013
157. Guise, T. A., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98, 1544-1549 (1996
158. Zheng, Y., et al. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin. Exp. Metastasis 25, 559-567 (2008
159. Zheng, Y., et al. Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 71, 1012-1021 (2011
160. Ooi, L. L., et al. Vitamin D deficiency promotes growth of MCF 7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone 47, 795-803 (2010
161. Ooi, L. L., et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 70, 1835-1844 (2010
162. Corey, E., et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 65, 1710-1718 (2005
163. Corey, E., et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin. Cancer Res. 9, 295-306 (2003
164. Kiefer, J. A., et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin. Exp. Metastasis 21, 381-387 (2004
165. Ottewell, P. D., et al. OPG Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int. J. Cancer 137, 968-977 (2015
166. Libouban, H., Moreau, M. F., Basle, M. F., Bataille, R., & Chappard, D. Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. Bone 33, 283-292 (2003
167. Croucher, P. I., et al. Zoledronic acid treatment of 5T2MM bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 18, 482-492 (2003
168. Vanderkerken, K., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63, 287-289 (2003
169. Yaccoby, S., et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol. 116, 278-290 (2002
170. Oyajobi, B. O., & Mundy, G. R. Receptor activator of NF ?.B ligand, macrophage inflammatory protein 1a, and the proteasome: novel therapeutic targets in myeloma. Cancer 97, 813-817 (2003
171. Kollet, O., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 12, 657-664 (2006
172. Bataille, R., Chappard, D., & Basle, M. F. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 87, 4762-4769 (1996
173. Lund, T., Abildgaard, N., Andersen, T. L., Delaisse, J. M., & Plesner, T. Multiple myeloma: changes in serum C terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur. J. Haematol. 84, 412-420 (2010
174. Michaelson, M. D., Marujo, R. M., & Smith, M. R. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin. Cancer Res. 10, 2705-2708 (2004
175. Smith, M. R., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345, 948-955 (2001
176. Smith, M. R., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 169, 2008-2012 (2003
177. Greenspan, S. L., Nelson, J. B., Trump, D. L., & Resnick, N. M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann. Intern. Med. 146, 416-424 (2007
178. Klotz, L. H., et al. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur. Urol. 63, 927-935 (2013
179. Smith, M. R., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009
180. Smith, M. R., et al. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J. Bone Miner. Res. 26, 2827-2833 (2011
181. Nguyen, P. L., et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol. 67, 825-836 (2015
182. Perez, E. A., & Weilbaecher, K. Aromatase inhibitors and bone loss. Oncol. (Williston Park) 20, 1029-1039; discussion 1039-1048 (2006
183. Llombart, A., et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-Associated bone loss in postmenopausal women with early breast cancer: 12 month analysis of the E ZO FAST trial. Clin. Breast Cancer 12, 40-48 (2012
184. Silbermann, R., & Roodman, G. D. Bone effects of cancer therapies: pros and cons. Curr. Opin. Support. Palliat. Care 5, 251-257 (2011
185. Oyajobi, B. O., et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br. J. Haematol. 139, 434-438 (2007
186. Giuliani, N., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110, 334-338 (2007
187. Pennisi, A., et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am. J. Hematol. 84, 6-14 (2009
188. Garcia-Gomez, A., et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin. Cancer Res. 20, 1542-1554 (2014
189. Scullen, T., et al. Lenalidomide in combination with an activin A neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia 27, 1715-1721 (2013
190. Bolomsky, A., et al. Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. Exp. Hematol. 42, 516-525 (2014
191. Breitkreutz, I., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22, 1925-1932 (2008
192. Munemasa, S., et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int. J. Oncol. 33, 129-136 (2008
193. Bolzoni, M., et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp. Hematol. 41, 387-397 (2013
194. Friedlaender, G. E., Tross, R. B., Doganis, A. C., Kirkwood, J. M., & Baron, R. Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J. Bone Joint Surg. Am. 66, 602-607 (1984
195. Van Leeuwen, B. L., et al. Effect of single chemotherapeutic agents on the growing skeleton of the rat. Ann. Oncol. 11, 1121-1126 (2000
196. Rana, T., Chakrabarti, A., Freeman, M., & Biswas, S. Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFβ. PLoS ONE 8, e78043 (2013
197. Van Der Kraan, A. G., et al. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors. Biochem. J. 451, 235-244 (2013
198. Chai, R. C., et al. Molecular stress-inducing compounds increase osteoclast formation in a heat shock factor 1 protein-dependent manner. J. Biol. Chem. 289, 13602-13614 (2014
199. King, T. J., et al. Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF ?.B activation. Am. J. Pathol. 181, 121-129 (2012
200. Early Breast Cancer Trialists? Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-Analyses of individual patient data from randomised trials. Lancet 386, 1353-1361 (2015
201. Gnant, M., et al. Adjuvant denosumab in breast cancer (ABCSG 18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386, 433-443 (2015
202. Fizazi, K., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011
203. Saad, F., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458-1468 (2002
204. Morgan, G. J., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989-1999 (2010
205. Morgan, G. J., et al. Long-term follow up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin. Cancer Res. 19, 6030-6038 (2013
206. Coleman, R., Gnant, M., Morgan, G., & Clezardin, P. Effects of bone-targeted agents on cancer progression and mortality. J. Natl Cancer Inst. 104, 1059-1067 (2012
207. Coleman, R. E., et al. Breast-cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365, 1396-1405 (2011
208. Smith, M. R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379, 39-46 (2012
209. Nozawa, M., et al. Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naive prostate cancer with bone metastasis. Int. J. Clin. Oncol. 19, 693-701 (2014
210. Okegawa, T., et al. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naive prostate cancer in a multicenter clinical trial. Anticancer Res. 34, 4415-4420 (2014
211. Smith, M. R., et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J. Clin. Oncol. 32, 1143-1150 (2014
212. Bone, H. G., et al. Odanacatib, a cathepsin K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937-947 (2010
213. Lotinun, S., et al. Osteoclast-specific cathepsin K deletion stimulates S1P dependent bone formation. J. Clin. Invest. 123, 666-681 (2013
214. Duong, L. T., Wesolowski, G. A., Leung, P., Oballa, R., & Pickarski, M. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol. Cancer Ther. 13, 2898-2909 (2014
215. Power, C. A., et al. A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate 69, 1613-1623 (2009
216. Godebu, E., et al. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J. Transl Med. 12, 275 (2014
217. Valta, M. P., et al. Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin. Exp. Metastasis 31, 573-584 (2014
218. Sipkins, D. A., et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435, 969-973 (2005
219. Runnels, J. M., et al. Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J. Biomed. Opt. 16, 011006 (2011
220. Conway, J. R., Carragher, N. O., & Timpson, P. Developments in preclinical cancer imaging: innovating the discovery of therapeutics. Nat. Rev. Cancer 14, 314-328 (2014
221. Chtanova, T., et al. Real-time interactive two-photon photoconversion of recirculating lymphocytes for discontinuous cell tracking in live adult mice. J. Biophoton. 7, 425-433 (2014